A
25.66
1.36 (5.60%)
| Previous Close | 24.30 |
| Open | 24.60 |
| Volume | 303,544 |
| Avg. Volume (3M) | 292,834 |
| Market Cap | 899,453,120 |
| Price / Book | 5.69 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2026 |
| Diluted EPS (TTM) | -2.30 |
| Total Debt/Equity (MRQ) | 19.01% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -53.00 M |
| Levered Free Cash Flow (TTM) | -39.36 M |
| Return on Assets (TTM) | -22.88% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alto Neuroscience, Inc. | Bullish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | 0.63 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.48% |
| % Held by Institutions | 77.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vestal Point Capital, Lp | 31 Dec 2025 | 2,485,000 |
| Commodore Capital Lp | 31 Dec 2025 | 1,823,196 |
| Perceptive Advisors Llc | 31 Dec 2025 | 1,784,393 |
| Vivo Capital, Llc | 31 Dec 2025 | 1,035,551 |
| 72 Investment Holdings, Llc | 31 Dec 2025 | 667,778 |
| 52 Weeks Range | ||
| Median | 28.00 (9.12%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 17 Feb 2026 | 28.00 (9.12%) | Buy | 19.26 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |